Cargando…

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod

Detalles Bibliográficos
Autores principales:	de Jong, Brigit A., van Kempen, Zoé L.E., Wattjes, Mike P., Smit, Patrick M., Peferoen, Laura, Berry, Daniella, Chamuleau, Martine E.D., de Jong, Daphne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047430/ https://www.ncbi.nlm.nih.gov/pubmed/30027107 http://dx.doi.org/10.1212/NXI.0000000000000483

Ejemplares similares

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017)

HSV-2–related hemophagocytic lymphohistiocytosis in a fingolimod-treated patient with MS
por: Ikumi, Kazuhiro, et al.
Publicado: (2016)

Tumefactive demyelination with a transient appearance of oligoclonal bands in MS under fingolimod
por: Okada, Kazumasa, et al.
Publicado: (2018)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS
por: Mehling, Matthias, et al.
Publicado: (2014)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Cytomegalovirus Encephalitis Under Fingolimod Mimicking Progressive Multifocal Leukoencephalopathy?
por: Oel, Dierk, et al.
Publicado: (2021)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Lymphocyte recovery after fingolimod discontinuation in patients with MS
por: Nagy, Sara, et al.
Publicado: (2020)

Narrative review based on fingolimod therapy in pediatric MS
por: Piri Cinar, Bilge, et al.
Publicado: (2023)

Continuing fingolimod after development of macular edema: A case report
por: Li, Vivien, et al.
Publicado: (2014)

COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
por: Barzegar, Mahdi, et al.
Publicado: (2020)

Anxiety is more important than depression in MS – Commentary
por: de Jong, Brigit A, et al.
Publicado: (2018)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients
por: Serpero, Laura D., et al.
Publicado: (2013)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Different MRI patterns in MS worsening after stopping fingolimod
por: Lapucci, Caterina, et al.
Publicado: (2019)

Fingolimod-associated PML with mild IRIS in MS: A clinicopathologic study
por: Nishiyama, Shuhei, et al.
Publicado: (2017)

Acute Treatment With Fingolimod Does Not Confer Long-Term Benefit in a Mouse Model of Intracerebral Haemorrhage
por: Diaz Diaz, Andrea C., et al.
Publicado: (2021)

Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center
por: Roux, Thomas, et al.
Publicado: (2017)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients
por: Piervincenzi, Claudia, et al.
Publicado: (2021)

The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
por: Mendeville, Matias, et al.
Publicado: (2022)

Beneficial effects of fingolimod in MS patients with high serum Sema4A levels
por: Koda, Toru, et al.
Publicado: (2018)

Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS
por: Fox, Edward J., et al.
Publicado: (2019)

Patient experience and practice trends in multiple sclerosis – clinical utility of fingolimod
por: Lee, Jong-Mi, et al.
Publicado: (2015)

Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK
por: Mazibrada, Gordon, et al.
Publicado: (2018)

Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
por: Veltmaat, Nick, et al.
Publicado: (2023)

Antidepressant activity of fingolimod in mice
por: di Nuzzo, Luigi, et al.
Publicado: (2015)

Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study
por: Fernández, Oscar, et al.
Publicado: (2020)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

Cardiovascular and Lymphoproliferative Diseases
por: Huston, Sharon M., et al.
Publicado: (2004)

Intermittent Atrioventricular Block following Fingolimod Initiation
por: Gialafos, E., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2u8ril75t9bp81icfvsepib55q